Ads
related to: lung cancer survival ratecancer.osu.edu has been visited by 10K+ users in the past month
Search results
Melanoma skin cancer vaccine being trialled on NHS halves risk of death or relapse
Daily Telegraph· 3 days agoMeanwhile, another study by the Danish biotech firm Evaxion and the Melanoma Institute Australia at...
Pfizer Highlights 'Unprecedented' 5 Year Data From Cancer Drug In Rare Form Of Advanced Lung Cancer...
Benzinga· 6 days agoAlso Read: Pfizer Agrees To Settle... Zantac. After five years of median follow-up, median...
Weight loss jabs have 'enormous potential' to cut risk of obesity-related cancer
Daily Express· 2 days agoWeight loss jabs such as Ozempic have “enormous potential” as a new weapon in the fight against ...
Phase III trial shows lorlatinib highly effective against ALK-positive non–small cell lung cancer
Medical Xpress· 2 days agoA large team of medical researchers and doctors has found via phase III clinical trial that the ALK inhibitor lorlatinib is highly effective for treating non–small cell lung
Improved Outcomes With Subcutaneous Amivantamab in NSCLC
Medscape· 5 days agoSubcutaneous amivantamab plus lazertinib may offer a survival benefit over intravenous administration, alongside dramatically reduced administration times, a new study suggests.
...I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer - Puma Biotechnology (NASDAQ:PBYI)
Benzinga· 3 days agoPuma Biotechnology, Inc. PBYI, a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor ...
Transplant in Unresectable Colorectal Liver Metastases?
Medscape· 15 hours agoLiver transplant plus chemotherapy offers a potential cure for carefully selected patients with...
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib(ROS1 Inhibitor) are...
ThePress.net· 5 days agoData were reported from 173 patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who were treated with taletrectinib.
RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer...
Forrest City Times-Herald· 6 days agoResults from the new analysis show the RYBREVANT® combination consistently and significantly improved progression-free survival (PFS) compared to osimertinib in patients with ...
MAIA Biotechnology reports promising Phase 2 trial results By Investing.com
Investing.com· 2 days agoThe trial assessed the efficacy of THIO sequenced with the immune checkpoint inhibitor cemiplimab in...
Ads
related to: lung cancer survival ratecancer.osu.edu has been visited by 10K+ users in the past month